BlackRock, Inc. filed Amendment No. 8 to Schedule 13G on October 27, 2026, reporting beneficial ownership of common stock of Kura Oncology Inc. as of the event date of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 7,908,832 shares of Kura Oncology Inc. common stock.
  • Percent of class: The reported position represents 8.9% of the outstanding class of common stock.
  • Sole voting power: BlackRock disclosed sole power to vote or direct the vote of 7,763,592 shares.
  • Sole dispositive power: BlackRock disclosed sole power to dispose or direct the disposition of 7,908,832 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power were reported as 0.
  • Amendment number: This filing is Amendment No. 8, triggered by the event date of September 30, 2026.
  • Filing type: BlackRock is classified as a parent holding company (HC), filing under Rule 13d-1(b).

BlackRock's Reported Position in Kura Oncology Common Stock

According to the filing, BlackRock, Inc., incorporated in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 8 to Schedule 13G with the SEC on October 27, 2026. The event date triggering the amendment was September 30, 2026. The filing covers shares of common stock of Kura Oncology Inc. (CUSIP 50127T109), whose principal executive offices are located at 4930 Directors Place, Suite 500, San Diego, CA 92121.

The filing discloses that BlackRock beneficially owns an aggregate of 7,908,832 shares, representing 8.9% of the class. Of those shares, BlackRock holds sole voting power over 7,763,592 and sole dispositive power over the full 7,908,832. Shared voting power and shared dispositive power are each reported as 0. The filing notes that the reported securities reflect holdings attributable to certain business units of BlackRock and its subsidiaries and affiliates, designated as "Reporting Business Units," consistent with SEC Release No. 34-39538 dated January 12, 1998. Securities beneficially owned by other business units whose beneficial ownership is disaggregated from the Reporting Business Units are not included.

On the question of receipt of dividends or sale proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Kura Oncology Inc." and that "no one person's interest in the common stock of Kura Oncology Inc is more than five percent of the total outstanding common shares." BlackRock certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026.

What Was Disclosed

BlackRock, Inc. filed Amendment No. 8 to Schedule 13G disclosing beneficial ownership of 7,908,832 shares, or 8.9%, of Kura Oncology Inc. common stock as of September 30, 2026, with sole voting power over 7,763,592 shares and sole dispositive power over all reported shares.